Literature DB >> 6800954

Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults.

J M Griffiss, B L Brandt, P L Altieri, G B Pier, S L Berman.   

Abstract

Serogroup Y and W135 Neisseria meningitidis capsular polysaccharide vaccines were tested as monovalent and divalent preparations in groups of 10 adult human volunteers at a dose of 50 (monovalent) or 100 micrograms (divalent) injected subcutaneously. Reactogenicity was low for the group Y vaccine and the group Y-W135 combined vaccine; 3 of 10 volunteers developed systemic reactions after group W135 vaccination. All three vaccines induced significant homologous and heterologous binding and bactericidal antibody. Except for group W135 bactericidal antibody, homologous responses exceeded heterologous responses, and divalent and monovalent vaccines induced equivalent homologous responses. Homologous bactericidal antibody responses were maintained for 4 weeks in 85% of group W135 vaccinates and in 100% of group Y vaccinates. Bactericidal antibody was induced in 11 of 11 group Y and 12 of 15 group W135 volunteers without preexisting respective bactericidal activities, regardless of which vaccine they received. For all three vaccines, antibody levels declined only slightly over 6 months. Prevaccination antibody levels positively affected postvaccination binding antibody levels, but not bactericidal levels.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6800954      PMCID: PMC350931          DOI: 10.1128/iai.34.3.725-732.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  The immunological responses observed in field studies in Africa with group A meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; J Etienne; W R Sanborn; R Triau; B Cvjetanović
Journal:  Prog Immunobiol Stand       Date:  1971

2.  Prevalence of meningococcal serogroups and description of three new groups.

Authors:  J R Evans; M S Artenstein; D H Hunter
Journal:  Am J Epidemiol       Date:  1968-05       Impact factor: 4.897

3.  Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera.

Authors:  J M Griffiss
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

4.  Group-y meningococcal disease. Twelve cases at an army training center.

Authors:  J D Smilack
Journal:  Ann Intern Med       Date:  1974-12       Impact factor: 25.391

5.  Prevention of meningococcal disease by group C polysaccharide vaccine.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; H Schneider; C Harkins
Journal:  N Engl J Med       Date:  1970-02-19       Impact factor: 91.245

6.  Structural determination of the polysaccharide antigens of Neisseria meningitidis serogroups Y, W-135, and BO1.

Authors:  A K Bhattacharjee; H J Jennings; C P Kenny; A Martin; I C Smith
Journal:  Can J Biochem       Date:  1976-01

7.  Effect of group-A meningococcal vaccine in army recruits in Finland.

Authors:  P H Mäkelä; H Käyhty; P Weckström; A Sivonen; O V Renkonen
Journal:  Lancet       Date:  1975-11-08       Impact factor: 79.321

8.  Vaccination against meningococcal group A disease in Finland 1974-75.

Authors:  H Peltola; P H Mäkelä; O ELO; O Pettay; O V Renkonen; A Sivonen
Journal:  Scand J Infect Dis       Date:  1976

9.  Group Y meningococcal disease in United States Air Force recruits.

Authors:  G M Koppes; C Ellenbogen; R J Gebhart
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

10.  Antibody responses to meningococcal polysaccharide vaccines.

Authors:  B L Brandt; M S Artenstein; C D Smith
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

View more
  15 in total

Review 1.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Authors:  S J Devi; W D Zollinger; P J Snoy; J Y Tai; P Costantini; F Norelli; R Rappuoli; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

3.  Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.

Authors:  C T Sacchi; A P Lemos; T Popovic; J C De Morais; A M Whitney; C E Melles; L M Brondi; L M Monteiro; M V Paiva; C A Solari; L W Mayer
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

4.  Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines.

Authors:  E C Beuvery; F Miedema; R van Delft; J Haverkamp
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

5.  Cross-protection by Pseudomonas aeruginosa polysaccharides.

Authors:  G B Pier
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

6.  Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines.

Authors:  J M Griffiss; B L Brandt; D D Broud
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

7.  Comparison of radioimmunoassay and enzyme-linked immunosorbent assay in measurement of antibodies to Neisseria meningitidis group A capsular polysaccharide.

Authors:  E C Beuvery; M H Kayhty; A B Leussink; V Kanhai
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

8.  Purification and vaccine potential of Klebsiella capsular polysaccharides.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

9.  Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide.

Authors:  I Vodopija; Z Baklaic; P Hauser; P Roelants; F E André; A Safary
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

10.  Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.

Authors:  L G Milagres; S R Ramos; C T Sacchi; C E Melles; V S Vieira; H Sato; G S Brito; J C Moraes; C E Frasch
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.